T1	p 23 39	asthma in adults
T2	p 230 260	31 adult asthmatic patients in
T3	i 46 87	sodium cromoglycate pressurized aerosol :
T4	i 122 212	Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo
T5	i 311 330	Sodium cromoglycate
T6	i 347 354	placebo
T7	i 760 790	favoured sodium cromoglycate .
T8	i 808 869	of bronchodilators ( theophylline and aerosol beta-stimulants
T9	i 933 962	sodium cromoglycate treatment
T10	i 975 984	placebo .
T11	i 1053 1105	sodium cromoglycate delivered by pressurized aerosol
T12	i 1136 1143	placebo
T13	i 1236 1250	bronchodilator
T14	o 368 382	breathlessness
T15	o 386 390	rest
T16	o 415 441	breathlessness on exertion
T17	o 471 487	quality of sleep
T18	o 538 577	morning peak expiratory flow rate value
T19	o 650 660	clinicians
T20	o 988 1000	side-effects
T21	o 1168 1186	asthmatic symptoms
T22	o 1214 1223	amount of